Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Starling Oncology (STLN) stock in plain English

Free brief · no signupStart here
STLNPublished Nov 15, 2026
Starling Oncology Inc
Healthcare · Medical Care Facilities
Operates outpatient cancer care clinics and administers specialty oncology pharmacy services. Treats patients through value-based Medicare insurance arrangements and direct physician visits.
Assets:
Community oncology clinicsOutpatient cancer centers providing specialized treatment
Starling Nexus platformProprietary care utilization management software
Specialty pharmaciesIn-house dispensing for complex chemotherapy medications
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

40
OPS ScoreOperating finances
Latest quote
-0.62%$3.18
$324.33M
n/a (loss)
$623.71M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was STLN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Starling Oncology (STLN) do?

Starling Oncology Inc (STLN) is a U.S.-listed company in Healthcare (Medical Care Facilities). What it does: Operates outpatient cancer care clinics and administers specialty oncology pharmacy services. Treats patients through value-based Medicare insurance arrangements and direct physician visits. Operates outpatient cancer clinics that manage treatment costs through capitated Medicare contracts and proprietary. It is worth $324.33M on the market and sold $623.71M over the last year.

Market cap
$324.33M
P/E ratio
None (reported a loss)
Annual sales
$623.71M
Sector
Healthcare
Industry
Medical Care Facilities
Brief updated
Nov 15, 2026

Brands and businesses behind STLN

  • Starling Nexus: A proprietary care management platform that coordinates cancer therapies and controls treatment utilization under insurance risk contracts.

STLN’s flags, in plain English

Each flag is a number from Starling Oncology’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Still Climbing

Sales up 21.8% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Insiders Hold

Insiders own 30% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Cheap on Cash Flow

Priced at 17.2 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Burning Cash

Losing money, profit margin of -4.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about STLN

How big is Starling Oncology?

Starling Oncology’s market cap is $324.33M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $623.71M: what customers paid the company over the last year, before any costs.

What is STLN’s P/E ratio?

STLN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with STLN?

Rising specialty drug acquisition costs compress operating margins across fee-for-service treatment protocols. That is one risk on Starling Oncology’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Starling Oncology’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. STLN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card